Jade Biosciences, Inc. Common Stock (JBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, JBIO trades at $23.38 with a market cap of $1.09B and a P/E ratio of -7.26. JBIO moved +6.35% today. Year to date, JBIO is +77.90%; over the trailing twelve months it is +202.53%. Its 52-week range spans $6.57 to $28.00. Analyst consensus is strong buy with an average price target of $35.67. Rallies surfaces JBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own JBIO include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Jade Biosciences, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $23.38 |
| Market Cap | $1.09B |
| P/E Ratio | -7.26 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.00 |
| 52-Week Low | $6.57 |
| Volume | 14.14K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-127.41M |
| Gross Margin | 0.00% |
8 analysts cover JBIO: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.67.